Based on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases.
Metabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at €0.02 per share reserved to specified investors.
Researchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.
An international research consortium provides data demonstrating that SARS-CoV-2 antibody tests are only useful for population-based analyses.
Two companies have presented a novel vaccination concept that might protect risk groups from new SARS-CoV-2 variants.
French Abivax SA has received a €36m non-dilutive funding from Bpifrance for its ABX464 Covid-19 programme.
4TEEN4 Pharmaceuticals GmbH published data suggesting that high plasma levels of dipeptidyl peptidase 3 were indicative for upcoming multiple organ failure in burn patients.
The funding pot of the Innovation Medicines Initiative has been boosted to €117m. IMI has also selected eight projects to fund.
British researchers have deciphered the glycosylation pattern of the viral spike protein of SARS-CoV-2 laying the foundation for vaccine development.